The rapid approvals of rare disease drugs continue. The most recent approval is Alexion Pharmaceuticals’ Soliris injection for intravenous use. Soliris treats adults with neuromyelitis Optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody...